Importantly, although EGFR and ALK mutations are found mostly in patients with history of no smoking or light smoking who have adenocarcinoma, genotyping should be offered to all patients with advanced NSCLC if treatment with specific TKIs is available. Here, EGFR is linked to non-small cell lung carcinoma.